Overview
Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is a rare and poorly understood interstitial lung disease characterized by chronic fibrosis affecting the pleura and subpleural parenchyma, predominantly in the upper lobes of the lungs. This condition is marked by distinctive clinical, radiological, and pathological features, including pleural thickening, upper lobe volume loss, and potential progression to respiratory failure. Given its rarity and often delayed diagnosis, iPPFE poses significant challenges in clinical management. Early recognition is crucial as it can influence treatment strategies and outcomes, potentially delaying irreversible respiratory decline and premature mortality. 12Pathophysiology
The pathophysiology of iPPFE revolves around abnormal proliferation and deposition of elastic fibers within the pleura and subpleural lung parenchyma, leading to structural changes that impair lung function. This fibrotic process is thought to originate from an aberrant wound healing response or chronic inflammation, although the exact initiating factors remain elusive. At the molecular level, dysregulation of transforming growth factor-beta (TGF-β) signaling pathways likely plays a pivotal role in promoting fibroblast activation and excessive collagen and elastic fiber deposition. These cellular and molecular alterations result in progressive stiffening of the lung tissue, compromising gas exchange and leading to characteristic radiological findings such as pleural thickening and upper lobe volume loss. The interplay between these pathological processes underscores the need for further research into potential therapeutic targets that could modulate fibrotic pathways. 12Epidemiology
Idiopathic pleuroparenchymal fibroelastosis has a notably low incidence, making precise epidemiological data scarce. It predominantly affects middle-aged to elderly individuals, with no clear sex predilection reported in current literature. Geographic distribution patterns are not well delineated, suggesting a sporadic occurrence rather than a geographically concentrated prevalence. Given its recent recognition and underdiagnosis, trends over time are difficult to ascertain, but there is an increasing awareness that iPPFE may be more prevalent than previously thought. Continued surveillance and reporting from diverse populations are essential to refine these epidemiological insights. 2Clinical Presentation
Patients with iPPFE typically present with progressive dyspnea, often exacerbated by exertion, and may report chronic cough, sometimes with sputum production. Unexplained weight loss and fatigue are common systemic symptoms reflecting the advanced nature of the disease. Radiological findings are crucial for diagnosis, including bilateral pleural thickening, particularly with a left scalloped appearance, upper lobe volume loss, and areas of consolidation with bronchograms. Red-flag features include acute exacerbations that might mimic pneumothorax or severe respiratory infections, necessitating prompt diagnostic evaluation to rule out complications such as spontaneous pneumothoraces or bronchopleural fistulae. 12Diagnosis
The diagnosis of iPPFE involves a multidisciplinary approach combining clinical history, imaging, and histopathological examination. Key diagnostic steps include:
Clinical History and Physical Examination: Focus on symptoms of chronic respiratory distress and systemic involvement.
Imaging: High-resolution computed tomography (HRCT) is essential, showing characteristic pleural thickening, upper lobe volume loss, and reticulation.
Histopathology: Lung biopsy demonstrating abnormal elastic fiber proliferation in the pleura and subpleural regions is definitive. Elastic fiber stains are particularly useful for confirming the diagnosis.
Screening for Pulmonary Hypertension: Transthoracic echocardiography (TTE) is used initially; definitive diagnosis via right heart catheterization may be required in tertiary care settings if PH is suspected.Specific Criteria and Tests:
HRCT Findings: Bilateral pleural thickening, upper lobe volume loss, reticulation, and bronchovascular bundle thickening.
Biopsy Requirements: Presence of abnormal elastic fiber deposition in pleura and subpleural lung tissue.
Pulmonary Hypertension Screening: TTE showing estimated pulmonary artery systolic pressure ≥ 35 mmHg; confirmatory right heart catheterization if indicated.
Differential Diagnosis: Differentiating from other interstitial lung diseases such as usual interstitial pneumonia (UIP) and desquamative interstitial pneumonia (DIP) based on imaging and histopathological features. 12Differential Diagnosis
Usual Interstitial Pneumonia (UIP): Distinguished by more diffuse involvement and honeycombing on biopsy rather than the focal pleuroparenchymal changes seen in iPPFE.
Desquamative Interstitial Pneumonia (DIP): Characterized by alveolar wall inflammation and macrophage accumulation without significant elastic fiber proliferation.
Lymphangioleiomyomatosis (LAM): Typically affects women of childbearing age and involves cystic changes predominantly in the lower lobes.
Chronic Eosinophilic Pneumonias: Marked by peripheral eosinophilia and characteristic histopathological findings of eosinophilic infiltration, which are absent in iPPFE. 2Management
First-Line Management
Supportive Care: Focus on symptom management including supplemental oxygen, pulmonary rehabilitation, and nutritional support.
Medications: Corticosteroids (e.g., prednisone 1 mg/kg/day) may be considered initially to reduce inflammation, though evidence is limited.
- Monitoring: Regular assessment of lung function, weight, and signs of infection.Second-Line Management
Immunosuppressive Agents: If corticosteroids are ineffective or contraindicated, consider agents like mycophenolate mofetil (1-2 g bid) or azathioprine (1-2 mg/kg/day).
- Monitoring: Regular blood counts, liver function tests, and renal function.
Anti-fibrotic Therapy: Nintedanib or pirfenidone may be explored based on their efficacy in other fibrotic lung diseases, though specific data for iPPFE are lacking.
- Monitoring: Liver function tests, gastrointestinal symptoms.Refractory Cases / Specialist Escalation
Lung Transplantation: Consider for patients with end-stage respiratory failure unresponsive to medical therapy.
- Evaluation: Comprehensive pre-transplant assessment including cardiac evaluation, lung allocation score, and psychosocial evaluation.
Pulmonary Hypertension Management: If PH develops, consider endothelin receptor antagonists (e.g., bosentan 62.5 mg twice daily) or phosphodiesterase-5 inhibitors (e.g., sildenafil 25 mg tid).
- Monitoring: Regular echocardiograms, right heart catheterization as needed, and assessment of exercise capacity.Contraindications:
Severe comorbidities precluding surgery or prolonged immunosuppression.
Active infections or uncontrolled comorbidities like severe heart failure. 12Complications
Spontaneous Pneumothorax: Increased risk due to lung parenchymal fragility; requires prompt chest tube insertion.
Bronchopleural Fistulae: Post-surgical complications; may necessitate prolonged management with chest tubes and antibiotics.
Progressive Respiratory Failure: Leads to need for mechanical ventilation and eventual consideration for lung transplantation.
Pulmonary Hypertension: Can develop and worsen prognosis; requires specialized management with targeted therapies.
- Referral Triggers: Acute respiratory decompensation, suspected complications, or refractory symptoms necessitating multidisciplinary input. 2Prognosis & Follow-Up
The prognosis for iPPFE is generally poor, with many patients experiencing progressive respiratory decline leading to respiratory failure. Key prognostic indicators include the extent of lung involvement, presence of pulmonary hypertension, and functional status. Recommended follow-up intervals typically include:
Monthly Initial Assessments: During active disease progression.
Quarterly Follow-Ups: Post-initial stabilization to monitor disease progression and manage symptoms.
Annual Comprehensive Evaluations: Including lung function tests, imaging, and clinical assessments to adjust management strategies.Regular monitoring helps in early detection of complications and timely intervention. 12
Special Populations
Elderly Patients: Often present with more advanced disease; management focuses on supportive care and symptom alleviation.
Comorbidities: Presence of other chronic diseases complicates treatment; individualized care plans are essential.
Pregnancy: Limited data; management requires careful consideration of maternal and fetal risks, often necessitating multidisciplinary consultation. 2Key Recommendations
Early Recognition and Diagnosis: Utilize HRCT with elastic fiber stains for definitive diagnosis. (Evidence: Moderate)
Comprehensive Clinical Evaluation: Include TTE for screening pulmonary hypertension, with right heart catheterization when indicated. (Evidence: Moderate)
Supportive Care as Primary: Focus on symptom management and nutritional support. (Evidence: Expert opinion)
Consider Immunosuppressive Therapy: For refractory cases, explore mycophenolate mofetil or azathioprine. (Evidence: Weak)
Monitor for Complications: Regularly assess for spontaneous pneumothorax and bronchopleural fistulae. (Evidence: Expert opinion)
Evaluate for Lung Transplantation: In end-stage disease unresponsive to medical therapy. (Evidence: Expert opinion)
Manage Pulmonary Hypertension: Use targeted therapies like endothelin receptor antagonists if PH develops. (Evidence: Moderate)
Regular Follow-Up: Schedule frequent assessments to monitor disease progression and adjust treatment. (Evidence: Expert opinion)
Multidisciplinary Approach: Involve pulmonologists, radiologists, and transplant specialists for comprehensive care. (Evidence: Expert opinion)
Consider Anti-fibrotic Agents: Explore nintedanib or pirfenidone based on individual patient response and tolerance. (Evidence: Weak) 12References
1 Cueto-Robledo G, Guerrero-Velazquez JF, Roldan-Valadez E, Graniel-Palafox LE, Cervantes-Naranjo FD, Cueto-Romero HD et al.. Pulmonary Hypertension or Pulmonary Arterial Hypertension in Idiopathic Pleuroparenchymal Fibroelastosis: An Updated Comprehensive Review. Current problems in cardiology 2022. link
2 Becker CD, Gil J, Padilla ML. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity?. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008. link